Advances have brought cautious hope for patients with this progressive and deadly disease. Intravenous prostanoids are still the most effective long-term medications, but oral options are available for select patients who are closely monitored. General internists and specialists in pulmonary, cardiac, and rheumatic diseases each have their role in managing these patients.